Composition comprising high purity pyrrole derivative and method for preparation thereof
The present invention relates to a composition comprising high purity pyrrole derivative and method for preparation thereof. The present invention particularly relates to compositions comprising Saroglitazar magnesium having purity of 99.0% or more, and one or more of an aldehyde compound of Formula (II), diketo oxirane compound of Formula (III), hydroxy methyl compound of Formula (IV) or dimer compound of Formula (V), relative to saroglitazar magnesium, each present in an amount of about 0.15% or less, respectively, by weight, when measured by area percentage of HPLC.
1. A composition comprising saroglitazar magnesium having a purity of about 99.0% or more by weight, and one or more of an aldehyde compound of Formula (II), a diketo oxirane compound of Formula (III), and a hydroxy methyl compound of Formula (IV), each of the compounds of Formula (II), Formula (III), or Formula (IV), when present, is in a detectable amount of about 0.15% or less, relative to saroglitazar magnesium by weight, when measured by area percentage of HPLC,
2. The composition according to claim 1 , wherein the composition comprises saroglitazar magnesium having a purity of about 99.5% or more by weight, and one or more of the aldehyde compound of Formula (II), the diketo oxirane compound of Formula (III), or the hydroxy methyl compound of Formula (IV), each of the compound of Formula (II), Formula (III), or Formula (IV), when present, is in a detectable amount of about 0.15% or less, relative to saroglitazar magnesium by weight, when measured by area percentage of HPLC.
3. The composition according to claim 1 , wherein the composition comprises saroglitazar magnesium having a purity of about 99.0% or more by weight, and the aldehyde compound of Formula (II) is present in a detectable amount of about 0.15% or less, relative to saroglitazar magnesium by weight, when measured by area percentage of HPLC.
4. The composition according to claim 1 , wherein the composition comprises saroglitazar magnesium having a purity of about 99.0% or more by weight, and the diketo oxirane compound of Formula (III) is present in a detectable amount of about 0.15% or less, relative to saroglitazar magnesium by weight, when measured by area percentage of HPLC.
5. The composition according to claim 1 , wherein the composition comprises saroglitazar magnesium having a purity of about 99.0% or more by weight, and the hydroxy methyl compound of Formula (IV) is present in a detectable amount of about 0.15% or less, relative to saroglitazar magnesium by weight, when measured by area percentage of HPLC.
6. The composition according to claim 1 , wherein the aldehyde compound of Formula (II), the diketo oxirane compound of Formula (III), and the hydroxy methyl compound of Formula (IV), each of the compounds of Formula (II), Formula (III), or Formula (IV), when present, is in a detectable amount of about 0.15%, or less by weight, relative to saroglitazar magnesium, after storage for 6 months at 40° C.±2° C. temperature and 75% ±5% relative humidity, or at 25° C.±2° C. temperature and 60% ±5% relative humidity, when measured by area percentage of HPLC.
7. A compound selected from an aldehyde compound of Formula (II), a diketo oxirane compound of Formula (III), and a hydroxymethyl compound of Formula (IV),
8. A process for the preparation of the substantially pure saroglitazar magnesium, wherein the process comprises:
(a) reacting a hydroxy compound (3A) with a mesylate compound (2B) in a one or more solvents in the presence of a base to obtain an alkoxy ester compound of Formula (VI);
(b) hydrolyzing the alkoxy ester compound of Formula (VI) with a base in one or more solvents at a temperature below 25° C. to obtain a reaction mixture;
(c) adjusting pH of the reaction mixture to 2.0 to 6.0;
(d) extracting the reaction mixture with one or more organic solvents to obtain an organic layer;
(e) treating the organic layer with S-(−)-α-methylbenzyl amine to obtain saroglitazar S-(−)-α-methylbenzyl amine (SMBA) salt of Formula (VII);
(f) purifying the saroglitazar SMBA salt with one or more solvents to obtain pure saroglitazar SMBA salt; and
treating the pure saroglitazar SMBA salt with magnesium source to obtain the composition comprising substantially pure saroglitazar magnesium.
9. The process according to claim 8 , wherein the reaction mixture at step (b) is washed with one or more organic solvents to obtain an aqueous layer and adjusting the pH of the aqueous layer to 2.0 to 6.0.
10. The process according to claim 8 , wherein the solvent at step (a) is one or more of alcohols selected from methanol, ethanol, isopropanol, 2-propanol, 1-butanol, and t-butyl alcohol; ketones selected from acetone, butanone, and methyl isobutyl ketone; esters selected from ethyl acetate, isopropyl acetate, t-butyl acetate, and isobutyl acetate; chlorinated hydrocarbons selected from methylene dichloride, ethylene dichloride, and chlorobenzene;
hydrocarbons selected from pentane, hexane, heptane, and cyclohexane; ethers selected from tetrahydrofuran, 1,4-dioxane, diisopropyl ether, diethyl ether, and methyl tert-butyl ether; or mixture thereof.
11. A composition comprising saroglitazar magnesium, wherein the saroglitazar magnesium is present in an amount of about 99.0% or more by weight, by area percentage of HPLC, and one or more of an aldehyde compound of Formula (II), a diketo oxirane compound of Formula (III), and a hydroxy methyl compound of Formula (IV), each of the compounds of Formula (II), Formula (III), or Formula (IV), when present, is in a detectable amount of about 0.15% or less by weight, relative to saroglitazar magnesium, by area percentage of HPLC, after storage for 6 months at 40° C.±2° C. temperature and 75% ±5% relative humidity or at 25° C.±2° C. temperature and 60±5% relative humidity,
12. A pharmaceutical composition comprising saroglitazar magnesium having a purity of about 99.0% or more by weight, and one or more of an aldehyde compound of Formula (II), a diketo oxirane compound of Formula (III), and a hydroxy methyl compound of Formula (IV), each of the compounds of Formula (II), Formula (III), or Formula (IV), when present, is in a detectable amount of about 0.15% or less, relative to saroglitazar magnesium by weight, when measured by area percentage of HPLC, together with pharmaceutically acceptable excipients, diluents and carriers,